Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKesson
Mallinckrodt
Boehringer Ingelheim
Harvard Business School
Johnson and Johnson

Last Updated: January 17, 2022

DrugPatentWatch Database Preview

Investigational Drug Information for OTO-104


Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug OTO-104?

OTO-104 is an investigational drug.

There have been 25 clinical trials for OTO-104. The most recent clinical trial was a Phase 3 trial, which was initiated on January 13th 2021.

The most common disease conditions in clinical trials are Meniere Disease, Otitis, and Otitis Media. The leading clinical trial sponsors are Otonomy, Inc., Sorlandet Hospital HF, and OHSU Knight Cancer Institute.

There is one US patent protecting this investigational drug and thirty-seven international patents.

Recent Clinical Trials for OTO-104
TitleSponsorPhase
OTO-313 in Subjects With Unilateral Subjective TinnitusOtonomy, Inc.Phase 2
Nasal Breathing and Physical CapacitySorlandet Hospital HFPhase 4
Tranexamic Acid Versus Epinephrine During Exploratory TympanotomyAssiut UniversityN/A

See all OTO-104 clinical trials

Clinical Trial Summary for OTO-104

Top disease conditions for OTO-104
Top clinical trial sponsors for OTO-104

See all OTO-104 clinical trials

US Patents for OTO-104

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
OTO-104 ⤷  Try it Free Heterocyclic compounds useful in the treatment of disease Epigen Biosciences, Inc. (San Diego, CA) ⤷  Try it Free
OTO-104 ⤷  Try it Free Pyrazol-3-ones that activate pro-apoptotic BAX Dana-Farber Cancer Institute, Inc. (Boston, MA) ⤷  Try it Free
OTO-104 ⤷  Try it Free Heterocyclic compound Takeda Pharmaceutical Company Limited (Osaka, JP) ⤷  Try it Free
OTO-104 ⤷  Try it Free Small molecules for the modulation of MCL-1 and methods of modulating cell death, cell division, cell differentiation and methods of treating disorders Dana-Farber Cancer Institute, Inc. (Boston, MA) ⤷  Try it Free
OTO-104 ⤷  Try it Free Phosphonate compounds for treatment of medical disorders Achillion Pharmaceuticals, Inc. (New Haven, CT) ⤷  Try it Free
OTO-104 ⤷  Try it Free IBAT inhibitors for the treatment of liver diseases Albireo AB (Gothenburg, SE) ⤷  Try it Free
OTO-104 ⤷  Try it Free Monomethylvaline compounds having phenylalanine side-chain modification at the C-terminus Seattle Genetics, Inc. (Bothell, WA) ⤷  Try it Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for OTO-104

Drugname Country Document Number Estimated Expiration Related US Patent
OTO-104 Australia AU2014232383 2033-03-15 ⤷  Try it Free
OTO-104 Australia AU2019202731 2033-03-15 ⤷  Try it Free
OTO-104 Australia AU2019288275 2033-03-15 ⤷  Try it Free
OTO-104 Brazil BR112015023267 2033-03-15 ⤷  Try it Free
OTO-104 Brazil BR112020025927 2033-03-15 ⤷  Try it Free
OTO-104 Canada CA2906931 2033-03-15 ⤷  Try it Free
OTO-104 Canada CA3046894 2033-03-15 ⤷  Try it Free
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKesson
Mallinckrodt
Boehringer Ingelheim
Harvard Business School
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.